Welcome to our dedicated page for AIM ImmunoTech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on AIM ImmunoTech stock.
AIM ImmunoTech Inc. develops immuno-pharma therapeutics led by Ampligen (rintatolimod), a dsRNA and selective TLR3 agonist immuno-modulator under development for late-stage pancreatic cancer and other cancer, viral disease and immune-disorder indications. Company news commonly covers clinical disclosures for Ampligen, including pancreatic cancer studies with checkpoint inhibitors, intellectual-property approvals, and regulatory designations.
Updates also address financing and capital-structure actions, such as rights offerings, preferred stock and warrant terms, at-the-market equity arrangements, shareholder voting matters, governance disclosures, operating results, and public-company reporting matters including audit and going-concern disclosures.
AIM ImmunoTech (NYSE American: AIM) disclosed that its audited consolidated financial statements for the year ended December 31, 2025 include an independent auditor's going concern emphasis of matter. This disclosure is required by NYSE American Section 610(b) and does not amend prior filings.
The company said management remains confident in its ability to raise funds and highlighted positive progress in the Phase 2 DURIPANC study of Ampligen plus durvalumab for metastatic pancreatic cancer; the next DURIPANC update is expected in June 2026.
AIM ImmunoTech (NYSE American: AIM) will host a live virtual investor Closing Bell Event on Thursday, April 16, 2026 at 4:00 PM ET. CEO Thomas K. Equels will give a corporate overview and business outlook and take live questions from investors.
A live video webcast will be available on the company Events page and a replay will be posted two hours after the presentation and accessible for 90 days.
AIM (NYSE: AIM) announced final approval of a Japanese patent covering Ampligen (rintatolimod) combined with checkpoint inhibitors for cancer treatment, with claims that include pancreatic cancer.
The patent was granted in September 2025 after a 6-month opposition period and expires December 20, 2039. AIM also holds related patents in the U.S. (expires August 9, 2039) and the Netherlands (expires December 19, 2039) and plans to pursue Japanese Orphan Drug Designation for Ampligen in pancreatic cancer. The company already holds U.S. and EU orphan designations.
AIM ImmunoTech (NYSE:AIM) announced the closing of its rights offering on March 6, 2026, which generated approximately $1.8 million in total subscriptions. Each purchased Unit was priced at $1,000 and consisted of one share of Series G convertible preferred stock and 2,000 Class G warrants.
The offering used a Form S-1 registration (No. 333-292085) declared effective by the SEC on February 10, 2026, with a prospectus supplement filed February 27, 2026. Maxim Group acted as dealer-manager.
AIM ImmunoTech (NYSE American: AIM) announced preliminary results of a rights offering that expired March 3, 2026, estimating aggregate subscriptions of approximately $1.8 million.
The offering sold Units at $1,000 per Unit (one Series G convertible preferred share plus 2,000 Class G warrants). Closing is anticipated on or about March 6, 2026, subject to customary conditions.
AIM ImmunoTech (NYSE American: AIM) signed an agreement with the PPD clinical research business of Thermo Fisher Scientific to design an anticipated Phase 3 trial of Ampligen for late-stage pancreatic cancer on March 2, 2026. AIM said its ongoing Phase 2 DURIPANC study with durvalumab is showing positive progress in PFS, OS and safety.
The Phase 2 study is investigator-initiated, open-label and expected to enroll up to 25 subjects in its Phase 2 portion; AIM plans to work with Thermo Fisher on Phase 3 design as enrollment completes later this year.
AIM ImmunoTech (NYSE:AIM) updated terms of its previously announced rights offering and reminded stockholders that the subscription period expires March 3, 2026 at 5:00 p.m. ET. Each subscription right now purchases one Unit for $1,000, consisting of one share of Series G Convertible Preferred Stock and 2,000 Class G common warrants.
Each Preferred share is convertible into 1,000 common shares (conversion price $1.00). Each warrant is exercisable for one common share at $1.00 per share and expires five years after issuance. Rights are non-transferable and exercise is irrevocable. The offering is made under an effective Form S-1 declared effective Feb. 10, 2026.
AIM ImmunoTech (NYSE American: AIM) extended the subscription period for its previously announced rights offering to 5:00 p.m. ET on March 3, 2026. The offering commenced on February 11, 2026 and subscription rights are non-transferable and exercisable only during the subscription period.
The company stated the SEC declared its Form S-1 effective on February 10, 2026. Maxim Group LLC is engaged as dealer-manager and Broadridge will act as subscription agent for receipt of completed rights certificates and payment.
AIM ImmunoTech (NYSE American: AIM) announced planned milestones and timelines for the Phase 2 DURIPANC study testing Ampligen (rintatolimod) with AstraZeneca’s durvalumab (Imfinzi) in metastatic pancreatic cancer.
Key items: 18 subjects enrolled to date; enrollment completion planned July 2026; full Ampligen dosing by August 2026; primary endpoint readout (6-month clinical benefit rate) in December 2026; secondary endpoint evaluations by June 2027. AIM published an updated corporate presentation prioritizing Ampligen approval in pancreatic cancer.
AIM ImmunoTech (NYSE American: AIM) commenced a rights offering distributing non-transferable Subscription Rights to holders of record as of Feb 10, 2026 to purchase up to 12,000 Units at $1,000 per Unit, implying $12.0 million gross proceeds if fully subscribed.
Each Unit includes one share of Series G convertible preferred (convertible into 833 common shares) and 1,666 five-year warrants exercisable at $1.20 per share. Subscription Period runs from Feb 11–27, 2026 (expected expiration 5:00 p.m. ET Feb 27, 2026).